Life Science Investing Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Life Science Investing Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Life Science Investing Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
Life Science Investing Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
